RNA formulation for immunotherapy

US11559587B2 · kind B2 · utility

Assignees

• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE
• BIONTECH SE · DE

Inventors

• Ugur Sahin · Mainz, DE
• Heinrich Haas · Mainz, DE
• Sebastian Kreiter · Mainz, DE
• Mustafa Diken · Mainz, DE
• Daniel Fritz · Mainz, DE
• Martin Meng · Mainz, DE
• Lena Mareen Kranz · Mainz, DE
• Kerstin Reuter · Darmstadt, DE

Key dates

• Filing date: Sep 23, 2019
• Grant date: Jan 24, 2023
• Expiry date: Oct 9, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.